The Knownwell CMO points to sleep apnea and MASH approvals as coverage routes, and says she expects retatrutide on the market next year.
Recap by typeshit. Full story at Dermatology Times.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The supplement ingredient is pitched by the company as a non-stimulant for cognition. Human trials only start in December 2026, with larger studies planned for 2027.
An older explainer sorting the weight loss market into approved medications, telehealth compounded drugs, online gray market peptides and supplements.
Loading…